Plain-English translation of NCT03414502 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing how well different medications work for treating rheumatoid arthritis, and which patients are most likely to benefit from each one. Researchers will enroll up to 400 people with rheumatoid arthritis who are starting a new medication—such as , , , or one of several other options. By studying how patients respond and looking at their blood work and genetic information, the study aims to predict which people will have the best results with specific treatments.
Right now, doctors cannot reliably predict which arthritis patients will respond well to which medication, so treatment often involves trial and error. This study hopes to identify early warning signs—such as blood markers or genetic factors—that could help doctors choose the most effective medication for each person from the start.
You likely qualify if…
You likely don't qualify if…
You will start taking one of several arthritis medications (your doctor will help choose which one based on your health and history) and return for follow-up visits at 8 weeks and 16 weeks. At each visit, your doctor will check how much your symptoms have improved, perform blood tests, and ask about any side effects. The study lasts 16 weeks total, and researchers will use your results and blood work to help understand which patients respond best to each treatment.
AI-generated summary from trial data · Jun 22, 2026 · Not medical advice
United States